Last updated on June 28, 2026 · Originally published June 16, 2026
A new pilot study is adding to the growing body of evidence that psilocybin – the active compound in magic mushrooms — can meaningfully reduce depression symptoms, particularly when paired with structured psychological support.
The study, published earlier this month, looked at combining psilocybin with cognitive behavioral therapy (CBT) – a pairing that researchers describe as well-tolerated and highly effective. Participants showed what the researchers characterized as profound improvements in mood and emotional regulation.
It’s a small study, and pilot data always comes with caveats about scale and reproducibility. But it fits a pattern that’s becoming harder to dismiss. Just this week, a separate study from the University of Toronto published in JAMA Psychiatry raised important methodological questions about how psychedelic clinical trials are designed, specifically, that most participants can tell whether they received the drug or the placebo, which complicates what the reported effects actually prove.
That’s a legitimate scientific concern, and the field is actively grappling with it. But even accounting for those limitations, the consistency of positive results across multiple research groups and trial designs is notable.
On the policy side, the U.S. DEA increased its 2026 production quotas for psilocybin and psilocin specifically to support expanding clinical research – a quiet but meaningful signal that federal appetite for psychedelic medicine is growing, not shrinking.
The UC Berkeley Center for the Science of Psychedelics also launched a new study this month looking at whether psilocybin can support healthy brain aging in older adults, a direction that, if it yields results, could eventually make psychedelic medicine relevant to a much broader population than the current focus on treatment-resistant depression and PTSD.
Sources: PsyPost, June 2026; University of Toronto / JAMA Psychiatry, June 2026; UC Berkeley News, June 2026.
